Compare CBK & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBK | CCCC |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | United States | United States |
| Employees | 298 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 483.7M | 404.7M |
| IPO Year | 2025 | 2020 |
| Metric | CBK | CCCC |
|---|---|---|
| Price | $34.76 | $3.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 31.7K | ★ 2.2M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | 16.14 | ★ 16.45 |
| EPS | ★ 0.70 | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $8.05 | N/A |
| P/E Ratio | $49.01 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $23.24 | $1.69 |
| 52 Week High | $35.78 | $5.17 |
| Indicator | CBK | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 43.81 |
| Support Level | $33.33 | $3.40 |
| Resistance Level | $34.46 | $3.91 |
| Average True Range (ATR) | 0.69 | 0.23 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 45.39 | 9.76 |
Commercial Bancgroup Inc is a bank holding company. Through its subsidiary, it operates as a full-service community banking institution offering traditional consumer and commercial products and services to businesses and individuals in select markets in Kentucky, North Carolina, and Tennessee. In Tennessee, its service areas include the metropolitan statistical areas of Nashville Davidson, Murfreesboro, Franklin, Knoxville, and the Tri Cities region of Kingsport, Bristol, and Johnson City, as well as Claiborne County, Cocke County, Union County, Hamblen County, and their surrounding areas.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.